Join the Zepbound group to help and get support from people like you.
Zepbound News (Page 2)
Zepbound Now Available Through Hims & Hers
WEDNESDAY, April 2, 2025 – The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform. The company said Tuesday it now provides access...
GLP-1 Drug Use For Weight Loss Has Soared, Costing Billions
TUESDAY, April 1, 2025 – The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says. The number of people...
More Type 1 Diabetics Are Obese, Taking GLP-1 Drugs
MONDAY, March 31, 2025 – Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new...
Tirzepatide, Semaglutide Not Cost-Effective at Current Prices
WEDNESDAY, March 19, 2025 – Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health Forum. Jennifer H....
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
TUESDAY, March 18, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 – For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers...
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance
FRIDAY, March 7, 2025 – The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the ...
No Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration Pneumonia
THURSDAY, March 6, 2025 – Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published...
Obesity On The Rise Worldwide, Report Says
TUESDAY, March 4, 2025 – More than half of adults and a third of children and teens worldwide will be overweight or obese by 2050, a comprehensive global analysis has concluded. Overweight and...
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
MONDAY, March 3, 2025 – Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or...
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Seniors
MONDAY, Feb. 24, 2025 – For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared...
Weight-Loss Drugs Could Help Extend Life of Replacement Joints
MONDAY, Feb. 24, 2025 (HealthDay news) – Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, a new study suggests. People...
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
FRIDAY, Feb. 21, 2025 – For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1...
Can GLP-1 Meds Harm Your Eyes?
MONDAY, Feb. 10, 2025 – Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye trouble, according...
New Facial Plastic Surgery Survey Illustrates Impact of GLP-1 Receptor Agonists
FRIDAY, Feb. 7, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of facial plastic surgery, according to the results of...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome